167 related articles for article (PubMed ID: 38459598)
1. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual comparison of
Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
8. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [
Chen Z; Fu F; Li F; Zhu Z; Yang Y; Chen X; Jia B; Zheng S; Huang C; Miao W
Mol Imaging Biol; 2018 Oct; 20(5):846-856. PubMed ID: 29497956
[TBL] [Abstract][Full Text] [Related]
10. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
11. [
Zheng S; Chen Z; Huang C; Chen Y; Miao W
Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
[TBL] [Abstract][Full Text] [Related]
12. Noninferiority of
Dai D; Rollo FD; Bryant J; Kim EE
Contrast Media Mol Imaging; 2018; 2018():8969714. PubMed ID: 29736155
[No Abstract] [Full Text] [Related]
13. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
[TBL] [Abstract][Full Text] [Related]
16. Potential utility of [
Li Y; Deng L; Feng Y; Liu L; Lv F; Qiu L
Eur Radiol; 2023 Dec; 33(12):9378-9389. PubMed ID: 37454338
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
[TBL] [Abstract][Full Text] [Related]
18. Quantitative
Coskun N; Cagdas B; Yildirim N
Hell J Nucl Med; 2022; 25(2):132-137. PubMed ID: 35913859
[TBL] [Abstract][Full Text] [Related]
19. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
20. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
